Zheng M, Wang S, Tang K, Kong R, Wang X, Zhou J
Proc Natl Acad Sci U S A. 2024; 122(1):e2413890121.
PMID: 39739815
PMC: 11725943.
DOI: 10.1073/pnas.2413890121.
Cui Y, Zhang Y, Yang C
Cell Death Discov. 2024; 10(1):511.
PMID: 39715768
PMC: 11666742.
DOI: 10.1038/s41420-024-02280-0.
Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K
J Exp Clin Cancer Res. 2024; 43(1):312.
PMID: 39609700
PMC: 11603874.
DOI: 10.1186/s13046-024-03218-1.
Rinotas V, Iliaki K, Pavlidi L, Meletakos T, Mosialos G, Armaka M
Cell Death Dis. 2024; 15(8):584.
PMID: 39122678
PMC: 11316070.
DOI: 10.1038/s41419-024-06966-2.
Bastidas R, Kedzior M, Davidson R, Walsh S, Dolat L, Sixt B
Elife. 2024; 12.
PMID: 38358795
PMC: 10942603.
DOI: 10.7554/eLife.87386.
Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote liver tumorigenesis.
Gao B, Wu X, Bu L, Jiang Q, Wang L, Liu H
Sci Adv. 2024; 10(6):eadk2285.
PMID: 38324694
PMC: 10849599.
DOI: 10.1126/sciadv.adk2285.
Mechanisms underlying linear ubiquitination and implications in tumorigenesis and drug discovery.
Li J, Liu S, Li S
Cell Commun Signal. 2023; 21(1):340.
PMID: 38017534
PMC: 10685518.
DOI: 10.1186/s12964-023-01239-5.
Deubiquitylating Enzymes in Cancer and Immunity.
Ren J, Yu P, Liu S, Li R, Niu X, Chen Y
Adv Sci (Weinh). 2023; 10(36):e2303807.
PMID: 37888853
PMC: 10754134.
DOI: 10.1002/advs.202303807.
CYLD in health and disease.
Marin-Rubio J, Raote I, Inns J, Dobson-Stone C, Rajan N
Dis Model Mech. 2023; 16(6).
PMID: 37387450
PMC: 10320722.
DOI: 10.1242/dmm.050093.
The Potential of Cylindromatosis (CYLD) as a Therapeutic Target in Oxidative Stress-Associated Pathologies: A Comprehensive Evaluation.
Huang Z, Tan Y
Int J Mol Sci. 2023; 24(9).
PMID: 37176077
PMC: 10179184.
DOI: 10.3390/ijms24098368.
MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
Minderman M, Lantermans H, Gruneberg L, Cillessen S, Bende R, van Noesel C
Blood Cancer J. 2023; 13(1):37.
PMID: 36922488
PMC: 10017792.
DOI: 10.1038/s41408-023-00809-7.
Genotoxicity-Stimulated and CYLD-Driven Malignant Transformation.
Erol A
Cancer Manag Res. 2022; 14:2339-2356.
PMID: 35958947
PMC: 9362849.
DOI: 10.2147/CMAR.S373557.
Map7D2 and Map7D1 facilitate microtubule stabilization through distinct mechanisms in neuronal cells.
Kikuchi K, Sakamoto Y, Uezu A, Yamamoto H, Ishiguro K, Shimamura K
Life Sci Alliance. 2022; 5(8).
PMID: 35470240
PMC: 9039348.
DOI: 10.26508/lsa.202201390.
IKK-mediated CYLD phosphorylation and cellular redox activity.
Erol A
Mol Med. 2022; 28(1):14.
PMID: 35109788
PMC: 8811971.
DOI: 10.1186/s10020-022-00439-y.
Cellular Deubiquitylating Enzyme: A Regulatory Factor of Antiviral Innate Immunity.
Long S, Yang L, Dang W, Xin S, Jiang M, Zhang W
Front Microbiol. 2021; 12:805223.
PMID: 34966378
PMC: 8710732.
DOI: 10.3389/fmicb.2021.805223.
Immune dysregulation in SHARPIN-deficient mice is dependent on CYLD-mediated cell death.
Ang R, Chan M, Legarda D, Sundberg J, Sun S, Gillespie V
Proc Natl Acad Sci U S A. 2021; 118(50).
PMID: 34887354
PMC: 8685717.
DOI: 10.1073/pnas.2001602118.
IκB kinase promotes Nrf2 ubiquitination and degradation by phosphorylating cylindromatosis, aggravating oxidative stress injury in obesity-related nephropathy.
Chen Y, Hong H, Lei Y, Zou J, Yang Y, He L
Mol Med. 2021; 27(1):137.
PMID: 34711178
PMC: 8555227.
DOI: 10.1186/s10020-021-00398-w.
Regulation of CYLD activity and specificity by phosphorylation and ubiquitin-binding CAP-Gly domains.
Elliott P, Leske D, Wagstaff J, Schlicher L, Berridge G, Maslen S
Cell Rep. 2021; 37(1):109777.
PMID: 34610306
PMC: 8511506.
DOI: 10.1016/j.celrep.2021.109777.
Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and oxidative stress response.
Snyder N, Silva G
J Biol Chem. 2021; 297(3):101077.
PMID: 34391779
PMC: 8424594.
DOI: 10.1016/j.jbc.2021.101077.
Inhibitory feedback control of NF-κB signalling in health and disease.
Prescott J, Mitchell J, Cook S
Biochem J. 2021; 478(13):2619-2664.
PMID: 34269817
PMC: 8286839.
DOI: 10.1042/BCJ20210139.